Bionano Genomics shares fall 12.59% after-hours as revenue declines and market doubts growth prospects.

Bionano Genomics (NASDAQ:BNGO) fell 12.59% in after-hours trading amid concerns over its recent revenue decline and market skepticism about future growth prospects. The stock’s price-to-sales (P/S) ratio of 0.5x, significantly lower than industry peers, reflects investor doubts despite analysts forecasting 29% annual revenue growth over the next three years. The article highlights a 14% year-over-year revenue drop and notes that the market appears unconvinced by optimistic projections, potentially due to perceived risks or instability. Additionally, the company faces four warning signs in its investment analysis, two of which are critical, further contributing to downward pressure. The decline underscores a lack of confidence in Bionano’s ability to deliver on growth expectations, leading to the sharp after-hours sell-off.